News
OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the ...
--AIM ImmunoTech Inc. today announced positive preliminary data from the Phase 1 b/2 study evaluating the combination of AIM’ s Ampligen ® and AstraZeneca’ s anti-PD-L1 immune checkpoint ...
OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM” or the "Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 ...
OCALA, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced positive preliminary data from the Phase 1b/2 study (“DURIPANC”) evaluating the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback